

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

WILLIAM ERNEST PULLMAN ET AL.

Serial No.: 10/661,951

Filed: September 12, 2003

For: UNIT DOSAGE FORM

Attorney Docket No. 29342/39617

Group Art Unit: 3661

Examiner: Unassigned

I hereby certify that this paper is being deposited with the United States Postal Service with sufficient postage, as first class mail, in an envelope addressed to:
Commissioner for Patents P.O. Box 1450
Alexandria, VA 22313-1450

Dated: February 6, 2004

James J. Napoli
Registration No. 32,361
Attorney for Applicants

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Sir:

Pursuant to their duty of disclosure under 37 C.F.R. §1.56, applicants hereby bring to the examiner's attention patents and publications that may be material to the examination of the above-identified application. Therefore, in compliance with 37 C.F.R. §1.97 and §1.98, applicants enclose a completed Form PTO-1449 listing the possibly pertinent patents and publications.

In accordance with 37 C.F.R. §1.98(d), copies of the patents and publications not enclosed herein were provided in a prior application that applicants

rely upon for an earlier filing date under 35 U.S.C. §120. Copies of nonenclosed documents listed in the attached Form PTO-1449 were provided to, or cited by, the examiner of the following patent application, now U.S. Patent No. 6,348,602:

William Ernest Pullman et al. Serial No. 10/031,556 Filing Date: October 19, 2001 Title: Unit Dosage Form

If the examiner needs a new copy of a patent or publication listed on the enclosed Form PTO-1449, applicants can provide such a copy.

This Information Disclosure Statement is submitted more than three months after the filing date of the above-identified application, and, to applicants' knowledge, before the mailing date of a first Office Action on the merits. Therefore, under 37 C.F.R. \$1.97(b), this Information Disclosure Statement shall be considered by the Patent Office.

The Commissioner, however, is hereby authorized to charge any fee which may be required during the pendency of this application under 37 C.F.R. 1.16 or 37 C.F.R. 1.17 to Deposit Account No. 13-2855. A duplicate copy of this Transmittal is enclosed herewith.

Respectfully submitted,

MARSHALL, GERSTEIN & BORUN LLP

Ву

James J. Napoli (Registration No. 32,361)
Attorneys for Applicants
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606
(312) 474-6300

Chicago, Illinois February 6, 2004



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	

Complete if Known			
Application Number	10/661,951		
Filing Date	09/12/2003		
First Named Inventor	Pullman et al.		
Group Art Unit	3661		
Examiner Name	Unassigned		
Attorney Docket Number	29342/39617		

U.S. PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY
		5,859,006	01/12/1999
		6,140,329	10/2000
		6,451,807	09/17/2002

FOREIGN PATENT DOCUMENTS			
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY
	ļ	WO 95/19978 (PCT)	07/27/1995
		WO 97/03675 (PCT)	06/02/1997
		WO 99/59584 (PCT)	11/25/1999
		WO 00/20033 (PCT)	04/13/2000

		OTHER PRIOR ART – NONPATENT LITERATURE DOCUMENTS		
Examiner Cite No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		Israel, The Pharmaceutical Journal, 261, pp. 164-165 (1998).		
		Goldenberg, Clinical Therapeutics, 20, No. 6, pp. 1033-1048 (1998).		
		WPIDS AN 2000-339026, Furitsu et al., JP 19990276134, September, 1999 (Abstract).		
		NDA 20-895 (New Drug Application) Sildenafil for Male Impotence, pp. 99-103 and 183-187, 22 January 1996, author unknown.		

Examiner	,	Date	
Signature		Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.